GA²LEN/EAACI pocket guide for allergen‐specific immunotherapy for allergic rhinitis and asthma

<jats:sec><jats:label /><jats:p> <jats:bold>To cite this article:</jats:bold> Zuberbier T, Bachert C, Bousquet PJ, Passalacqua G, Walter Canonica G, Merk H, Worm M, Wahn U, Bousquet J. GA<jats:sup>2</jats:sup>LEN/EAACI pocket guide for allergen‐specific immunotherapy for allergic rhinitis and asthma. <jats:italic>Allergy</jats:italic> 2010; <jats:bold>65</jats:bold>: 1525–1530.</jats:p></jats:sec><jats:sec><jats:title>Abstract</jats:title><jats:p>This pocket guide is the result of a consensus reached during several GA<jats:sup>2</jats:sup>LEN and EAACI meetings. The aim of the current pocket guide is to offer a comprehensive set of recommendations on the use of immunotherapy in allergic rhinoconjunctivitis and asthma in daily practice. This pocket guide is meant to give simple answers to the most frequent questions of practitioners in Europe, including ‘practising allergists’, general practitioners and any other physicians with special interest in allergen‐specific immunotherapy (SIT). It is not a long or detailed scientific review of the topic. However, the recommendations in this pocket guide were compiled following an in‐depth review of existing guidelines and publications, including the 1998 EAACI position paper, the 1998 WHO Position Paper on SIT and the 2001 Allergic Rhinitis and its Impact on Asthma (ARIA). It is also based on the ARIA update 2008 (prepared in collaboration with GA<jats:sup>2</jats:sup>LEN), the ‘Sub‐lingual Immunotherapy: WAO Position Paper 2009’ (from the World Allergy Organisation) and the Methodology paper of ARIA. The recommendations cover patient selection, allergen extract to be used, route of administration of SIT (in particular, sublingual and subcutaneous immunotherapy), and necessary precautions to be followed in using SIT.</jats:p></jats:sec>